943319-70-8 Ponatinib AKSci J61145
 
 
Loading Please Wait...
  J61145    
Ponatinib
, 95%
 
AP24534




IDENTITY
CAS Number:943319-70-8
MDL Number:MFCD17215203
MF:C29H27F3N6O
MW:532.57
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:95%
Physical Form (at 20°C):Solid
Melting Point:123-128°C
Density:1.3
Refractive Index:1.62
Long-Term Storage:Store long-term at -20°C
DOT/IATA TRANSPORT INFORMATION
UN #:UN2811
Hazard Class:6.1; Poison
Packing Group:II
A hazmat fee may apply to certain package sizes. Please check pricing table for an indicator of applicable hazmat fees.

BIOLOGICAL INFO
Solubility:DMSO =105mg/mL, Water <1.2mg/mL, Ethanol =105mg/mL
Application(s):Multi-target inhibitor of Abl, PDGFRa, VEGFR2, FGFR1 and Src
Form:Free base
Research Area:Leukemia

REVIEW

 Ponatinib (AP24534) is a novel potent, orally available small molecule multitargeted kinase inhibitor and its primary cellular target is the Bcr-Abl tyrosine kinase protein which is constitutively active and promotes the progression of CML. Ponatinib is unique in that it is especially useful in the treatment of resistant CML because it inhibits the tyrosine kinase activity of Abl and T315I mutant kinases. Other targets that ponatinib inhibits are members of the VEGFR, PDGFR, FGFR, EPH receptors and SRC families of kinases, and KIT, RET, TIE2, and FLT3.

REFERENCES
[1]Pound, H. B.; Ho, V. Q.; Pinilla-Ibarz, J. Ponatinib: multitargeted kinase inhibitor pan-BCR-ABL inhibitor oncolytic: AP-24534. Drugs of the Future. (2011) 36(11): 807-812.
[2] Narayanan V, Pollyea DA, Gutman JA, Jimeno A. Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Drugs Today (Barc). (2013) Apr;49(4): 261-9.
[3] Thomas, Xavier. Is AP24534 (Ponatinib) the next treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia? Bulletin du Cancer. (2011) 98(7): 761-767.
[4] Zou, Dong; Huang, Wei-Sheng; Thomas, R. Mathew; Romero, Jan Antionette C.; Qi, Jiwei; Wang, Yihan; Zhu, Xiaotian; Shakespeare, William C.; Sundaramoorthi, Rajeswari; Metcalf, Chester A., III; et al Preparation of bicyclic heteroaryl alkynyl arenes as protein kinase inhibitors for treatment of cancer PCT Int. Appl. (2007), WO 2007075869 A2 20070705.

GLOBALLY HARMONIZED SYSTEM (GHS)

Pictograms

Signal Word
Danger

Hazard Statements
H301+H311+H331

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501


Current as of April 23, 2024


Download SDS Request COA

All products are stocked and shipped from San Francisco Bay Area, California, USA.

⚠️
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.

These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.

Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.

New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.



CATEGORIES

 APIs and Bioactives >


PubChem